TABLE 4.
Susceptibility of C. parapsilosis to fluconazole and voriconazole by specimen type
| Specimen type/site (total no. of isolates)a | Antifungal agent | No. of isolates tested | % of isolates from siteb | % of isolatesc
|
||
|---|---|---|---|---|---|---|
| S | SDD | R | ||||
| Blood (14,887) | Fluconazole | 2,834 | 19.0 | 93.1 | 2.7 | 4.2 |
| Voriconazole | 2,755 | 96.8 | 1.0 | 2.2 | ||
| NSBF (6,055) | Fluconazole | 373 | 6.2 | 94.1 | 2.7 | 3.2 |
| Voriconazole | 368 | 97.3 | 0.5 | 2.2 | ||
| Urine (18,168) | Fluconazole | 806 | 4.4 | 91.1 | 4.5 | 4.5 |
| Voriconazole | 771 | 96.1 | 1.8 | 2.1 | ||
| Respiratory (39,523) | Fluconazole | 1,008 | 2.6 | 94.2 | 3.4 | 2.4 |
| Voriconazole | 979 | 97.3 | 1.2 | 1.5 | ||
| Skin or soft tissue (8,290) | Fluconazole | 1,220 | 14.7 | 95.1 | 3.0 | 1.9 |
| Voriconazole | 1,196 | 97.9 | 1.2 | 0.9 | ||
| Genital (31,157) | Fluconazole | 1,009 | 3.2 | 95.7 | 2.3 | 2.0 |
| Voriconazole | 926 | 97.3 | 1.3 | 1.4 | ||
| Misc. NOS (23,303) | Fluconazole | 2,121 | 9.1 | 91.7 | 3.3 | 5.0 |
| Voriconazole | 2,046 | 95.7 | 2.0 | 2.3 | ||
a
That is, the total number of Candida isolates from each specimen type. Misc. NOS, miscellaneous, not otherwise specified.
b
C. parapsilosis as a percentage of all isolates from that specimen type.
c
S, SDD, and R are as defined in Table 2, footnote a.